Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data AC Immune SA files with the SEC in its annual reports.
In CHF millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
23.2
20.3
6.91
110
15.4
0
3.94
14.8
27.3
3.57
Research and development
25.8
32.7
44.3
50.4
59.5
62.3
60.3
54.6
62.6
56.4
Selling, general and administrative
7.9
10.1
12.5
16.1
18.6
17.9
Operating income
-10.5
-22.5
-49.6
44.5
-61.3
-79
-70.8
-53.6
-52.4
-69.3
Interest expense
0.33
1.93
0.18
0.58
0.36
0.18
0.13
0.19
Interest income
3.32
-4.06
0.13
0.3
0.08
6.49
0.07
1.04
3.2
1.87
Pre-tax income
-7.1
-26.4
-51
45.4
-61.9
-73
-70.7
-54.2
-50.9
-70.4
Income tax
0
0
0
0
0
0
0.01
0.01
0
0
Net income
-7.1
-26.4
-51
45.4
-61.9
-73
-70.8
-54.2
-50.9
-70.4
EPS, basic
-0.14
-0.46
-0.82
0.64
-0.86
-0.97
-0.85
-0.64
-0.51
-0.70
EPS, diluted
-0.14
-0.46
-0.82
0.64
-0.86
-0.97
-0.85
-0.64
-0.51
-0.70
Balance sheet
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
152
124
156
194
161
82.2
31.6
78.5
36.3
26.8
Total current assets
155
130
193
293
232
203
128
125
172
96.7
Property, plant and equipment
1.12
2.35
3.32
3.92
4.42
5.12
4.26
3.38
2.65
1.99
Lease right-of-use assets
2.19
2.26
2.22
2.91
2.81
3.51
5.44
4.54
Intangible assets
0
50.4
50.4
50.4
50.4
50.4
Total assets
156
132
197
299
239
261
186
183
231
154
Accounts payable
4.04
1.09
1.98
0.14
2.18
2
0.93
1.68
2.66
2.07
Total current liabilities
9.92
9.75
13.1
17.5
14
20
11.5
13.6
101
94.7
Lease liabilities
0
1.81
1.78
2.34
2.25
2.83
4.4
3.69
Total liabilities
13.7
15.2
18.9
26.8
23.3
29.5
16.9
22.2
119
109
Paid-in capital
188
188
298
347
347
431
431
475
479
482
Retained earnings
-46.9
-72.6
-122
-75.5
-133
-201
-264
-316
-368
-439
Total equity
142
117
178
272
215
232
169
161
112
44.9
Total liabilities and equity
156
132
197
299
239
261
186
183
231
154
Cash flow statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-7.1
-26.4
-51
45.4
-61.9
-73
-70.8
-54.2
-50.9
-70.4
Cash from operations
-5.65
-22.1
-44.1
55.2
-59.5
-65.7
-73.6
-60.4
65.8
-69.3
Capital expenditures
-0.9
-1.8
-1.86
-1.89
-1.71
-2.64
-1.24
-0.8
-0.58
-0.9
Cash from investing
-0.9
-1.84
-32
-66.9
28.3
-53.7
23.8
65.6
-105
63.5
Debt issued
0
0.2
0.2
0.2
0
0
Share buybacks
0
0
-0.1
0
0
Cash from financing
78.8
0.27
109
49.6
-0.8
40.7
-1.35
43.3
-1.12
-1.02
Exchange rate effect
3.44
-4.17
-1.18
-0.83
-0.7
-0.07
0.52
-1.58
-1.65
-2.74
Net change in cash
72.2
-23.7
33.3
38
-32
-78.6
Free cash flow
-6.55
-23.9
-45.9
53.3
-61.2
-68.3
-74.8
-61.2
65.3
-70.2
Interest paid
0
0
0.3
0.34
0.47
0.47
0.16
0.11
0.17
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. No valuation: the share price is quoted in a different currency than the statements.
Profitability
Metric
Value
How it is calculated
Operating margin
-1,940.0%
Operating income / revenue.
Pre-tax margin
-1,972.0%
Pre-tax income / revenue.
Net margin
-1,972.0%
Net income / revenue.
FCF margin
-1,964.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-1,938.0%
Cash from operations / revenue.
Return on assets (ROA)
-36.6%
Net income / average total assets.
R&D / revenue
1,580.0%
Research and development expense / revenue.
Capex / revenue
25.2%
Capital expenditures / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-86.9%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-3.2%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-25.4%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow growth, 1y
-205.2%
Operating cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow growth, 1y
-207.5%
Free cash flow vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-33.2%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-6.0%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-8.4%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.02x
Current assets / current liabilities.
Quick ratio
0.28x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.28x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
70.9%
Total liabilities / total assets.
Interest coverage
-363x
Operating income / interest expense.
Working capital
CHF 2.0M
Current assets - current liabilities.
Goodwill and intangibles / assets
32.7%
(Goodwill + intangible assets) / total assets.
Efficiency
Metric
Value
How it is calculated
Asset turnover
0.02x
Revenue / average total assets.
Fixed asset turnover
1.54x
Revenue / average property, plant and equipment.
Per share
Metric
Value
How it is calculated
EPS, diluted
-CHF 0.70
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-CHF 0.70
Net income per basic share, as reported (split-adjusted).
What was AC Immune SA's revenue in fiscal 2025?
AC Immune SA reported revenue of CHF 3.6M for fiscal 2025, 86.9% lower than the year before.
Was AC Immune SA profitable in fiscal 2025?
No. It reported a net loss of CHF 70.4M.
How much free cash flow did AC Immune SA generate in fiscal 2025?
Cash from operations of CHF 69.3M minus capital expenditures of CHF 900.0K left free cash flow of -CHF 70.2M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.